Last reviewed · How we verify
growth hormone and lirglutide
growth hormone and lirglutide is a Small molecule drug developed by Columbia University. It is currently FDA-approved.
The drug, a combination of growth hormone and lirglutide, is currently marketed by Columbia University. A key strength is the protection provided by the key composition patent, which expires in 2028. The primary risk is the lack of clear revenue data and undefined primary indication, which may limit market understanding and adoption.
At a glance
| Generic name | growth hormone and lirglutide |
|---|---|
| Sponsor | Columbia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of GH and Lirglutide on AgRP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- growth hormone and lirglutide CI brief — competitive landscape report
- growth hormone and lirglutide updates RSS · CI watch RSS
- Columbia University portfolio CI
Frequently asked questions about growth hormone and lirglutide
What is growth hormone and lirglutide?
Who makes growth hormone and lirglutide?
What development phase is growth hormone and lirglutide in?
Related
- Manufacturer: Columbia University — full pipeline
- Compare: growth hormone and lirglutide vs similar drugs
- Pricing: growth hormone and lirglutide cost, discount & access